“All around the world countries will be launching a campaign to “vaccinate” billions of pigs, cows, goats, and sheep over a period of nine months."
Genvax Technologies, a startup dedicated to bringing advances in self-amplifying mRNA (saRNA) vaccine production to animal health, has secured $6.5 million in series seed funding.
United Animal Health led the financing with participation from Johnsonville Ventures, Iowa Corn Growers Association, Summit Agricultural Group and Ag Startup Engine. This investor coalition represents animal health, nutrition, feed, meat packers and consumer products in the fight against existing and emerging threats to the food supply chain.
“The threat posed to producers and consumers by foreign animal diseases like African swine fever (ASF) and constantly mutating variants of swine influenza is extraordinary,” Joel Harris, CEO and co-founder of Genvax Technologies, said in a release. “The goal is to develop a vaccine that matches 100% to the specific strain when a disease outbreak occurs."
This funding moves the company a step forward to USDA and international regulatory approval of its vaccines in anticipation of any foreign animal disease outbreak, Genvax said in a release.